The Europe rapid test kit market was valued at US$ 5.24 billion in 2022 and is expected to reach US$ 7.76 billion by 2030; it is estimated to record a CAGR of 5.0% from 2022 to 2030.
In 2022, Singapore-based diagnostics manufacturer INEX Innovate, a pioneer in the women's and fetal health sector in Asia, has received a CE mark for OvaCis Rapid Test, its flagship solution for ovarian cancer. By the end of 2022, OvaCis-a first-of-its-kind point-of-care (POCT) test that distinguishes benign from malignant ovarian cysts in an operating room setting-is expected to make its debut in the EU and Southeast Asian markets.
In January 2022, OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing as well as sample collection technologies, launched the OraQuick HIV Self-Test, an oral swab-based in-home test for HIV-1 and HIV-2, for the European market. The test is accessible in six European countries: the UK, France, Germany, Italy, Spain, and Portugal.
In 2021, following the issuance of the CE certificate, FUJIFILM Europe GmbH was authorized to apply the CE mark and introduce an antigen test kit for the diagnosis of SARS-CoV-2 infection. The technique being utilized by Fujifilm is called proprietary silver amplification immunochromatography, and it is based on the same technology that is used to amplify the photos to be developed.
In December 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for a virtually guided BinaxNOW COVID-19 Ag Card (by Abbott) rapid test, indicated for the at-home use for detection of COVID-19. BinaxNOW is a widely distributed and one of the most affordable rapid tests, which provides results in minutes.
In July 2020, the FDA granted Emergency Use Authorization (EUA) for a rapid, point-of-care, SARS-CoV-2 diagnostic test for use with its broadly available BD Veritor Plus System. The new assay generates results in 15 minutes on an easy-to-use, highly portable instrument. The test was meant to improve access to COVID-19 diagnostics by providing real-time results and aiding quick decision-making while the patient is still in the testing facility.
Further, as per the endmalaria.org 2020 report, international sources provided 69% of total funding aiming for malaria control and elimination. The total funding for malaria control and elimination accounted for US$ 3.3 billion, including US$ 0.2 billion contributed by Germany. Thus, the rapid test kits market is likely to grow in Germany in the coming years with the rising prevalence of infectious disease such as diabetes, AIDS, tuberculosis, and malaria.
Strategic Initiatives by Manufacturers Drive Europe Rapid Test Kit Market
Manufacturers in the rapid test kits market emphasize on the adoption of strategies such as innovations, and product launches and approvals to maintain a competitive edge in the market. Such strategic initiatives by companies in the rapid test kits market benefit the overall market.In 2022, Singapore-based diagnostics manufacturer INEX Innovate, a pioneer in the women's and fetal health sector in Asia, has received a CE mark for OvaCis Rapid Test, its flagship solution for ovarian cancer. By the end of 2022, OvaCis-a first-of-its-kind point-of-care (POCT) test that distinguishes benign from malignant ovarian cysts in an operating room setting-is expected to make its debut in the EU and Southeast Asian markets.
In January 2022, OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing as well as sample collection technologies, launched the OraQuick HIV Self-Test, an oral swab-based in-home test for HIV-1 and HIV-2, for the European market. The test is accessible in six European countries: the UK, France, Germany, Italy, Spain, and Portugal.
In 2021, following the issuance of the CE certificate, FUJIFILM Europe GmbH was authorized to apply the CE mark and introduce an antigen test kit for the diagnosis of SARS-CoV-2 infection. The technique being utilized by Fujifilm is called proprietary silver amplification immunochromatography, and it is based on the same technology that is used to amplify the photos to be developed.
In December 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for a virtually guided BinaxNOW COVID-19 Ag Card (by Abbott) rapid test, indicated for the at-home use for detection of COVID-19. BinaxNOW is a widely distributed and one of the most affordable rapid tests, which provides results in minutes.
In July 2020, the FDA granted Emergency Use Authorization (EUA) for a rapid, point-of-care, SARS-CoV-2 diagnostic test for use with its broadly available BD Veritor Plus System. The new assay generates results in 15 minutes on an easy-to-use, highly portable instrument. The test was meant to improve access to COVID-19 diagnostics by providing real-time results and aiding quick decision-making while the patient is still in the testing facility.
Europe Rapid Test Kit Market Overview
The prevalence of the diabetes in Germany has been increasing significantly. According to the International Diabetes Federation, in 2021 ~62 million people were having diabetes. Moreover, according to the European Center for Disease Prevention and Control report, 8,641 malarial cases were registered in the European Union (EU) in 2019, of which 8,638 (>99%) were confirmed diagnoses. In September 2022, Germany signed an agreement worth US$ 1.34 billion with The Joint United Nations Programme on HIV/AIDS (UNAIDS) aiming to fight AIDS, tuberculosis, and malaria; with this, the country raised its contribution by 30% compared to 2019.Further, as per the endmalaria.org 2020 report, international sources provided 69% of total funding aiming for malaria control and elimination. The total funding for malaria control and elimination accounted for US$ 3.3 billion, including US$ 0.2 billion contributed by Germany. Thus, the rapid test kits market is likely to grow in Germany in the coming years with the rising prevalence of infectious disease such as diabetes, AIDS, tuberculosis, and malaria.
Europe Rapid Test Kit Market Segmentation
The Europe rapid test kit market is segmented based on type, product, technology, application, end user, and country. Based on type, the Europe rapid test kit market is segmented into rapid antigen testing, rapid antibody testing, and others. The rapid antigen testing segment held the largest market share in 2022.- In terms of product, the Europe rapid test kit market is bifurcated into over-the-counter rapid testing kit and professional rapid testing kit. The over-the-counter rapid testing kit segment held a larger market share in 2022.
- By technology, the Europe rapid test kit market is segmented into lateral flow assay, solid phase, agglutination, immunospot assay, and cellular component-based. The lateral flow assay segment held the largest market share in 2022.
- Based on application, the Europe rapid test kit market is categorized into blood glucose testing, infectious disease testing, pregnancy and fertility, cardiometabolic testing, and others. The blood glucose testing segment held the largest market share in 2022.
- In terms of end user, the Europe rapid test kit market is segmented into hospital and clinics, home care, diagnostics centers, and others. The hospital and clinics segment held the largest market share in 2022.
- Based on country, the Europe rapid test kit market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe rapid test kit market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Rapid Test Kits Market - Key Industry Dynamics
5. Rapid Test Kits Market - Europe Market Analysis
6. Europe Rapid Test Kits Market Analysis - by Type
7. Europe Rapid Test Kits Market Analysis - by Product
8. Europe Rapid Test Kits Market Analysis - by Technology
9. Europe Rapid Test Kits Market Analysis - by Application
10. Europe Rapid Test Kits Market Analysis - by End User
11. Europe Rapid Test Kits Market - Country Analysis
12. Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Becton Dickinson and Co
- Sysmex Partec GmbH
- ARKRAY Inc
- Fujirebio Europe NV
- bioMerieux SA
- Cepheid
- Meril Life Sciences Pvt Ltd
- QIAGEN NV
- OraSure Technologies Inc
- Guangzhou Wondfo Biotech Co Ltd
- Denka Co Ltd
- Abbott Laboratories
- Trinity Biotech Plc
- Bio-Rad Laboratories Inc
- Hologic Inc
- Premier Medical Corp Pvt Ltd
- DiaSorin SpA
- Beckman Coulter Inc
